More Ruconest territories for SOBI as Esteve returns rights to Pharming
This article was originally published in Scrip
Executive Summary
Pharming said it has reached a mutual agreement with Esteve to return the rights to market Ruconest (recombinant human C1 inhibitor) in Spain, Portugal, Andorra and Greece.